Skandinaviska Enskilda Banken AB publ Has $6.12 Million Stock Holdings in Zimmer Biomet Holdings, Inc. $ZBH

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 47.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,079 shares of the medical equipment provider’s stock after purchasing an additional 19,996 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Zimmer Biomet were worth $6,115,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC bought a new stake in shares of Zimmer Biomet during the 4th quarter worth about $204,000. Sivia Capital Partners LLC bought a new stake in Zimmer Biomet during the second quarter worth approximately $232,000. Nordea Investment Management AB grew its holdings in Zimmer Biomet by 7.3% during the second quarter. Nordea Investment Management AB now owns 17,839 shares of the medical equipment provider’s stock valued at $1,628,000 after purchasing an additional 1,210 shares during the last quarter. Private Trust Co. NA raised its position in shares of Zimmer Biomet by 14.6% in the second quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock valued at $98,000 after purchasing an additional 137 shares during the period. Finally, United Bank lifted its stake in shares of Zimmer Biomet by 10.7% in the second quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock worth $1,085,000 after buying an additional 1,153 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ZBH has been the topic of several recent analyst reports. Citigroup reiterated a “buy” rating on shares of Zimmer Biomet in a report on Wednesday, February 11th. The Goldman Sachs Group lowered Zimmer Biomet from a “neutral” rating to a “sell” rating and set a $93.00 price objective on the stock. in a research note on Friday, January 9th. UBS Group restated a “sell” rating and set a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Wells Fargo & Company lifted their price target on Zimmer Biomet from $93.00 to $98.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th. Finally, Barclays reduced their price objective on Zimmer Biomet from $104.00 to $100.00 and set an “underweight” rating for the company in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of “Hold” and a consensus price target of $106.20.

Zimmer Biomet Stock Up 0.9%

NYSE ZBH opened at $99.17 on Friday. Zimmer Biomet Holdings, Inc. has a 1-year low of $84.59 and a 1-year high of $114.44. The company has a market capitalization of $19.65 billion, a price-to-earnings ratio of 28.01, a PEG ratio of 2.01 and a beta of 0.62. The stock’s 50 day moving average is $90.50 and its two-hundred day moving average is $95.78. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 EPS for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion during the quarter, compared to the consensus estimate of $2.22 billion. During the same quarter last year, the company earned $2.31 EPS. Zimmer Biomet’s revenue was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is presently 27.12%.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.